Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Organogenesis Holdings Inc.
A regenerative-medicine company that grows living skin and tissue grafts to help wounds heal. Its best-known product, Apligraf, was the first living cell-based skin substitute approved by the U.S. Food and Drug Administration, and its PuraPly line treats chronic wounds like diabetic ulcers. Founded in 1985 in Cambridge, Massachusetts, the company's name reflects its mission of growing organs and tissues in the lab.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits